A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

Purpose: Aberrant mTOR pathway and somatostatin receptor signaling are implicated in thyroid cancer and offer potential therapeutic targets. We assessed the clinical efficacy of everolimus and Pasireotide long-acting release (LAR) in radioiodine-refractory differentiated thyroid cancer (DTC) and med...

Full description

Bibliographic Details
Main Authors:	Julie E. Bauman, Zhengjia Chen, Chao Zhang, James P. Ohr, Robert L. Ferris, Gerald M. McGorisk, Stephen Brandt, Sumathi Srivatsa, Amy Y. Chen, Conor E. Steuer, Dong M. Shin, Nabil F. Saba, Fadlo R. Khuri, Taofeek K. Owonikoko
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Cancers
Subjects:	thyroid cancer somatostatin receptor everolimus pasireotide combination medullary carcinoma
Online Access:	https://www.mdpi.com/2072-6694/14/11/2639

Similar Items

Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
by: Richard A. Feelders, et al.
Published: (2023-10-01)

Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation
by: Christiaan F. Mooij, et al.
Published: (2021-12-01)

Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
by: Xin He, et al.
Published: (2020-11-01)

Loss of efficacy of pasireotide after its re-administration: is there a reason why?
by: Stylianos Mandanas, et al.
Published: (2016-12-01)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
by: Feun LG, et al.
Published: (2018-01-01)

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study
by: Vittoria Favero, et al.
Published: (2024-02-01)

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
by: Rouland A, et al.
Published: (2021-02-01)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
by: Adrian F Daly, et al.
Published: (2019-04-01)

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly
by: Jan-Shun Chang, et al.
Published: (2016-06-01)

Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
by: Mônica Gadelha, et al.
Published: (2020-02-01)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
by: Przemysław Witek, et al.
Published: (2021-03-01)

The position of combined medical treatment in acromegaly
by: Eva C. Coopmans, et al.
Published: (2020-01-01)

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
by: Maria Fleseriu, et al.
Published: (2019-07-01)

Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors
by: Sebastian Gulde, et al.
Published: (2021-06-01)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01)

Pasireotide after Surgery for Persistent Cushing’s Disease
by: Dan Nicolae PADURARU, et al.
Published: (2019-12-01)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01)

Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy
by: Terri W. Jerkins, et al.
Published: (2019-03-01)

IGF-1 influences Everolimus activity in medullary thyroid carcinoma
by: Erica eGentilin, et al.
Published: (2015-05-01)

Everolimus in combination with octreotide LAR in thymic atypical carcinoid
by: Tadashi Sakane, et al.
Published: (2023-05-01)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
by: A. Ciresi, et al.
Published: (2018-01-01)

Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST<sub>2</sub> in Mediating Ligand Effects
by: Jessica Amarù, et al.
Published: (2021-04-01)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
by: Nelma Veronica Marques, et al.
Published: (2023-09-01)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
by: Rosa Maria Paragliola, et al.
Published: (2018-03-01)

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature
by: Hasan Husni, et al.
Published: (2022-03-01)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
by: Alessandro Mondin, et al.
Published: (2022-07-01)

A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation
by: Chunying Ma, et al.
Published: (2019-06-01)

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement
by: Sylvère Störmann, et al.
Published: (2024-02-01)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
by: Soraya Puglisi, et al.
Published: (2020-02-01)

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
by: Sandrine Oziel-Taieb, et al.
Published: (2022-04-01)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
by: Peter Wolf, et al.
Published: (2022-11-01)

Everolimus tedavisine bağlı interstisyel pnömoni
by: Nilüfer Aykaç Kongar, et al.
Published: (2016-12-01)

Pasireotide in the Personalized Treatment of Acromegaly
by: Manel Puig-Domingo, et al.
Published: (2021-03-01)

Acromegaly: Beyond surgery
by: Gaya Thanabalasingham, et al.
Published: (2013-01-01)

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
by: Donatella Treppiedi, et al.
Published: (2022-05-01)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
by: Mattia Barbot, et al.
Published: (2022-05-01)

AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center
by: Adrian F Daly, et al.
Published: (2019-03-01)